查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2110197

2026-2034年全球血友病治療市場規模、佔有率、趨勢和成長分析報告

Global Hemophilia Treatment Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 302 Pages | 商品交期: 最快1-2個工作天內

價格
簡介目錄

全球血友病治療市場預計將從2025年的171.4億美元成長至2034年的280.8億美元，2026年至2034年的複合年成長率（CAGR）為5.64%。全球血友病治療市場穩定成長，主要得益於血友病診斷病例的增加以及人們對早期治療重要性的認知不斷提高。作為一種遺傳性出血性疾病，血友病需要終身管理，因此對有效治療方法的需求持續存在。醫療基礎設施的改善和診斷工具的廣泛應用也促進了確診患者數量的增加，從而推動了已開發國家和新興市場市場的擴張。

生物技術和藥物研發的進步顯著改善了血友病患者的治療選擇。重組凝血因子、半衰期延長療法和非因子替代療法的引入提高了治療效果，並減少了注射次數。此外，製藥公司和研究機構加大投入，加速了旨在改善患者生活品質的創新療法的研發。

血友病治療市場預計將受益於基因療法和個人化醫療的快速發展。基因療法有望為患者提供長期甚至根治性的解決方案，從而改變治療方式。醫療保健支出的成長和專業治療中心的可近性提高，預計也將推動全球市場的持續成長。

我們的報告經過精心撰寫，旨在提供涵蓋廣泛行業和市場的全面且切實可行的洞察。每份報告都包含幾個關鍵組成部分，旨在幫助您全面了解市場環境：

市場概覽：本節對市場進行了清晰的說明，包括關鍵定義、分類以及當前行業格局的概述。

市場動態：對影響市場成長的主要促進因素、限制因素、機會和挑戰進行詳細評估。這包括技術發展、法律規範和不斷變化的行業趨勢等因素。

市場區隔分析：本部分根據產品類型、應用、最終用戶和地區將市場系統性地分類為若干關鍵細分市場。本部分揭示了每個細分市場的表現、成長潛力和市場貢獻。

競爭格局：我們對主要市場參與企業進行了詳細評估，包括其市場定位、產品系列、策略舉措和財務表現。這有助於深入了解競爭趨勢和主要參與者所採取的策略。

市場預測：本部分提供基於數據的市場規模和成長模式預測，預測期為指定時期。它綜合考慮了歷史趨勢、當前市場狀況和定量分析，以識別預期的未來趨勢。

區域分析：我們全面檢驗主要地理區域的市場表現，識別高成長領域和區域趨勢，並深入了解每個區域特有的市場機會。

新趨勢與新機會：識別關鍵市場趨勢、技術進步和新興投資機會。本部分重點在於潛在成長領域和未來產業趨勢。

客製化選項：我們提供靈活的報告客製化服務，以滿足您的特定需求。這包括額外的細分、國家/地區分析、競爭對手分析、客製化資料點或針對特定細分市場的洞察，從而更有效地支援您的策略決策。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

  • 市場譜系展望
  • 滲透率和成長前景分析
  • 價值鏈分析
  • 法律規範
    • 標準與合規性
    • 監管影響分析
  • 市場動態
    • 市場促進因素
    • 市場限制因素
    • 市場機遇
    • 市場挑戰
  • 波特五力分析
  • PESTLE分析

第4章 全球血友病治療市場：依疾病類型分類

  • 市場分析、洞察與預測
  • A型血友病A
  • B型血友病
  • 其他疾病類型

第5章 全球血友病治療市場：依產品分類

  • 市場分析、洞察與預測
  • 重組凝血因子濃縮物
  • 血漿衍生凝血因子濃縮物
  • 半衰期延長產品
  • 去氨加壓素
  • 抗纖溶溶劑
  • 基因治療產品

第6章 全球血友病治療市場：依患者類型分類

  • 市場分析、洞察與預測
  • 兒童
  • 成人

第7章 全球血友病治療市場：依治療方式分類

  • 市場分析、洞察與預測
  • 預防
  • 一經請求

第8章 全球血友病治療市場：依療法分類

  • 市場分析、洞察與預測
  • 因子替代療法
  • 非因子替代療法

第9章 全球血友病治療市場：依藥物類別分類

  • 市場分析、洞察與預測
  • 血管加壓素
  • 凝血因子

第10章 全球血友病治療市場：依給藥途徑分類

  • 市場分析、洞察與預測
  • 注射藥物
  • 鼻噴霧
  • 口服

第11章 全球血友病治療市場：依最終用途分類

  • 市場分析、洞察與預測
  • 醫院
  • 診所
  • 血友病治療中心
  • 其他最終用戶

第12章 全球血友病治療市場：依地區分類

  • 區域分析
  • 北美市場分析、洞察與預測
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲市場分析、洞察與預測
    • 英國
    • 法國
    • 德國
    • 義大利
    • 俄羅斯
    • 其他歐洲國家
  • 亞太市場分析、洞察與預測
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 東南亞
    • 其他亞太國家
  • 拉丁美洲市場分析、洞察與預測
    • 巴西
    • 阿根廷
    • 秘魯
    • 智利
    • 其他拉丁美洲國家
  • 中東和非洲市場分析、洞察與預測
    • 沙烏地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中東和非洲國家

第13章 競爭格局

  • 最新趨勢
  • 公司分類
  • 供應鏈和銷售管道合作夥伴（根據現有資訊）
  • 市場佔有率和市場定位分析（基於現有資訊）
  • 供應商情況（基於現有資訊）
  • 策略規劃

第14章：公司簡介

  • 主要公司的市佔率分析
  • 公司簡介
    • Bayer AG
    • Biogen Inc
    • BioMarin Pharmaceutical Inc
    • Biotest AG
    • CSL Behring LLC
    • Ferring BV
    • Genentech Inc
    • Kedrion SpA
    • Novo Nordisk A/S
    • Octapharma AG
    • Pfizer Inc
    • Sanofi SA
    • Swedish Orphan Biovitrum AB（Sobi）
    • Takeda Pharmaceutical Company Limited
簡介目錄
Product Code: VMR112115486

The global hemophilia treatment market size is expected to reach USD 28.08 Billion in 2034 from USD 17.14 Billion in 2025, growing at a CAGR of 5.64 during 2026-2034.The global hemophilia treatment market is growing steadily due to the increasing diagnosis of hemophilia and rising awareness about early treatment. Hemophilia, a genetic bleeding disorder, requires lifelong management, which has led to sustained demand for effective therapies. Improved healthcare infrastructure and greater availability of diagnostic tools have also contributed to the growing number of diagnosed patients, supporting market expansion across both developed and emerging economies.

Advancements in biotechnology and pharmaceutical research have significantly improved treatment options for hemophilia patients. The introduction of recombinant clotting factors, extended half-life therapies, and non-factor replacement therapies has enhanced treatment outcomes and reduced the frequency of injections. In addition, increasing investments by pharmaceutical companies and research institutions are accelerating the development of innovative therapies aimed at improving patient quality of life.

In the future, the hemophilia treatment market is expected to benefit from the rapid progress of gene therapy and personalized medicine approaches. Gene-based treatments have the potential to offer long-term or even curative solutions for patients, transforming the treatment landscape. Increasing healthcare expenditure and improved access to specialized treatment centers are also expected to drive continued market growth globally.

Our reports are carefully developed to deliver comprehensive and actionable insights across a wide range of industries and markets. Each report includes several essential components designed to provide a complete understanding of the market environment:

Market Overview: This section provides a clear introduction to the market, including key definitions, classifications, and an overview of the current industry landscape.

Market Dynamics: A detailed evaluation of the primary drivers, restraints, opportunities, and challenges shaping market growth. It covers factors such as technological developments, regulatory frameworks, and evolving industry trends.

Segmentation Analysis: A structured breakdown of the market into key segments based on product type, application, end-user, and geographic region. This section highlights the performance, growth potential, and contribution of each segment.

Competitive Landscape: An in-depth assessment of leading market participants, including their market positioning, product portfolios, strategic initiatives, and financial performance. It provides valuable insights into competitive dynamics and the strategies adopted by key players.

Market Forecast: Data-driven projections of market size and growth patterns over a defined forecast period. This section incorporates historical trends, current market conditions, and quantitative analysis to illustrate expected future developments.

Regional Analysis: A comprehensive review of market performance across major geographic regions, identifying high-growth areas and regional trends to better understand localized market opportunities.

Emerging Trends and Opportunities: Identification of significant market trends, technological advancements, and new investment opportunities. This section highlights potential growth areas and future industry developments.

Customization Options: We offer flexible customization services to tailor reports according to specific client requirements. This may include additional segmentation, country-level analysis, competitor profiling, customized data points, or focused insights on particular market segments to better support strategic decision-making.

MARKET SEGMENTATION

By Disease Type

  • Hemophilia A
  • Hemophilia B
  • Other disease types

By Product

  • Recombinant coagulation factor concentrates
  • Plasma-derived coagulation factor concentrates
  • Extended half-life products
  • Desmopressin
  • Antifibrinolytic agents
  • Gene therapy products

By Patient

  • Pediatric
  • Adult

By Treatment

  • Prophylaxis
  • On demand

By Therapy

  • Factor replacement therapy
  • Non-factor replacement therapy

By Drug Class

  • Vasopressin
  • Coagulation factors

By Route of Administration

  • Injectable
  • Nasal spray
  • Oral

By End-use

  • Hospitals
  • Clinics
  • Hemophilia treatment centers
  • Other end-users

COMPANIES PROFILED

  • Bayer AG, Biogen Inc., BioMarin Pharmaceutical Inc., Biotest AG, CSL Behring LLC, Ferring B.V., Genentech Inc., Kedrion S.p.A., Novo Nordisk A/S, Octapharma AG, Pfizer Inc., Sanofi SA, Swedish Orphan Biovitrum AB (Sobi), Takeda Pharmaceutical Company Limited

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL HEMOPHILIA TREATMENT MARKET: BY DISEASE TYPE 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Disease Type
  • 4.2. Hemophilia A Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Hemophilia B Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Other disease types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL HEMOPHILIA TREATMENT MARKET: BY PRODUCT 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Product
  • 5.2. Recombinant coagulation factor concentrates Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Plasma-derived coagulation factor concentrates Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Extended half-life products Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.5. Desmopressin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.6. Antifibrinolytic agents Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.7. Gene therapy products Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL HEMOPHILIA TREATMENT MARKET: BY PATIENT 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Patient
  • 6.2. Pediatric Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Adult Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL HEMOPHILIA TREATMENT MARKET: BY TREATMENT 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Treatment
  • 7.2. Prophylaxis Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. On demand Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL HEMOPHILIA TREATMENT MARKET: BY THERAPY 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Therapy
  • 8.2. Factor replacement therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Non-factor replacement therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL HEMOPHILIA TREATMENT MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 9.1. Market Analysis, Insights and Forecast Drug Class
  • 9.2. Vasopressin Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 9.3. Coagulation factors Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 10. GLOBAL HEMOPHILIA TREATMENT MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

  • 10.1. Market Analysis, Insights and Forecast Route Of Administration
  • 10.2. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 10.3. Nasal spray Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 10.4. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 11. GLOBAL HEMOPHILIA TREATMENT MARKET: BY END-USE 2022-2034 (USD MN)

  • 11.1. Market Analysis, Insights and Forecast End-use
  • 11.2. Hospitals Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 11.3. Clinics Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 11.4. Hemophilia treatment centers Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 11.5. Other end-users Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 12. GLOBAL HEMOPHILIA TREATMENT MARKET: BY REGION 2022-2034 (USD MN)

  • 12.1. Regional Outlook
  • 12.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 12.2.1 By Disease Type
    • 12.2.2 By Product
    • 12.2.3 By Patient
    • 12.2.4 By Treatment
    • 12.2.5 By Therapy
    • 12.2.6 By Drug Class
    • 12.2.7 By Route Of Administration
    • 12.2.8 By End-use
    • 12.2.9 United States
    • 12.2.10 Canada
    • 12.2.11 Mexico
  • 12.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 12.3.1 By Disease Type
    • 12.3.2 By Product
    • 12.3.3 By Patient
    • 12.3.4 By Treatment
    • 12.3.5 By Therapy
    • 12.3.6 By Drug Class
    • 12.3.7 By Route Of Administration
    • 12.3.8 By End-use
    • 12.3.9 United Kingdom
    • 12.3.10 France
    • 12.3.11 Germany
    • 12.3.12 Italy
    • 12.3.13 Russia
    • 12.3.14 Rest Of Europe
  • 12.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 12.4.1 By Disease Type
    • 12.4.2 By Product
    • 12.4.3 By Patient
    • 12.4.4 By Treatment
    • 12.4.5 By Therapy
    • 12.4.6 By Drug Class
    • 12.4.7 By Route Of Administration
    • 12.4.8 By End-use
    • 12.4.9 India
    • 12.4.10 Japan
    • 12.4.11 South Korea
    • 12.4.12 Australia
    • 12.4.13 South East Asia
    • 12.4.14 Rest Of Asia Pacific
  • 12.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 12.5.1 By Disease Type
    • 12.5.2 By Product
    • 12.5.3 By Patient
    • 12.5.4 By Treatment
    • 12.5.5 By Therapy
    • 12.5.6 By Drug Class
    • 12.5.7 By Route Of Administration
    • 12.5.8 By End-use
    • 12.5.9 Brazil
    • 12.5.10 Argentina
    • 12.5.11 Peru
    • 12.5.12 Chile
    • 12.5.13 Rest of Latin America
  • 12.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 12.6.1 By Disease Type
    • 12.6.2 By Product
    • 12.6.3 By Patient
    • 12.6.4 By Treatment
    • 12.6.5 By Therapy
    • 12.6.6 By Drug Class
    • 12.6.7 By Route Of Administration
    • 12.6.8 By End-use
    • 12.6.9 Saudi Arabia
    • 12.6.10 UAE
    • 12.6.11 Israel
    • 12.6.12 South Africa
    • 12.6.13 Rest of the Middle East And Africa

Chapter 13. COMPETITIVE LANDSCAPE

  • 13.1. Recent Developments
  • 13.2. Company Categorization
  • 13.3. Supply Chain & Channel Partners (based on availability)
  • 13.4. Market Share & Positioning Analysis (based on availability)
  • 13.5. Vendor Landscape (based on availability)
  • 13.6. Strategy Mapping

Chapter 14. COMPANY PROFILES OF GLOBAL HEMOPHILIA TREATMENT INDUSTRY

  • 14.1. Top Companies Market Share Analysis
  • 14.2. Company Profiles
    • 14.2.1 Bayer AG
    • 14.2.2 Biogen Inc
    • 14.2.3 BioMarin Pharmaceutical Inc
    • 14.2.4 Biotest AG
    • 14.2.5 CSL Behring LLC
    • 14.2.6 Ferring B.V
    • 14.2.7 Genentech Inc
    • 14.2.8 Kedrion S.p.A
    • 14.2.9 Novo Nordisk A/S
    • 14.2.10 Octapharma AG
    • 14.2.11 Pfizer Inc
    • 14.2.12 Sanofi SA
    • 14.2.13 Swedish Orphan Biovitrum AB (Sobi)
    • 14.2.14 Takeda Pharmaceutical Company Limited